Bioretec Ltd Registers Important Shareholding Notification Under Finnish Securities Act

Bioretec Ltd Reports Key Shareholding Change Under Finnish Regulations

On April 29, 2026, Bioretec Ltd (''Bioretec'') announced a significant shareholder notification in compliance with the Finnish Securities Markets Act. The company confirmed that Sp-Rahastoyhtiö Oy's investment fund, Säästöpankki Pienyhtiöt, has surpassed the critical threshold of 5% ownership in Bioretec's shares and voting rights, as reported under Chapter 9, Section 5 of the Act.

This development is particularly noteworthy for investors and stakeholders, as it reflects growing interest and confidence in Bioretec's innovative capabilities. According to the announcement, Sp-Rahastoyhtiö's current holding stands at 8.01%, which is based on a total of approximately 1.34 billion shares available in Bioretec.

The breakdown of the shareholding shows that there are no additional financial instruments affecting the holdings reported by Sp-Rahastoyhtiö. This clarity is essential within the context of financial regulations, ensuring transparency for existing and potential investors in Bioretec. The movement in shareholding comes as the company continues to make strides in the orthopedic medical device sector, leveraging its pioneering technologies.

Bioretec's Innovations and Future Outlook

Bioretec is recognized as a veteran in the development of biodegradable implants that enhance orthopedic care. Their unique technologies, particularly in creating a biological interface for active implants, catalyze bone growth and expedite fracture healing post-surgery.

One of their latest innovations, the RemeOs™ product line, represents a significant advancement in the field. Utilizing a high-performance magnesium alloy and hybrid composite materials, these implants are designed to be absorbed by the body, thereby negating the need for surgical removal after fulfilling their purpose in fracture healing.

The regulatory approvals for RemeOs have strengthened Bioretec's position in the market, with the U.S. granting authorization in March 2023 and Europe following suit with CE mark approval in January 2025. This progression speaks volumes about Bioretec's commitment to providing effective and patient-friendly treatment options.

Additionally, their Activa product line features fully bioabsorbable orthopedic implants constructed from a unique, self-reinforced PLGA. Both CE marked and FDA cleared, these implants serve a broad spectrum of indications across adult and pediatric patients, further demonstrating Bioretec's comprehensive approach to orthopedic solutions.

In a landscape where healthcare advancements are paramount, Bioretec Ltd stands as a guiding force, emphasizing healing through absorption. The company aims to cultivate patient-friendly alternatives that streamline recovery and enhance surgical outcomes.

Bioretec's trajectory indicates an enthusiastic embrace of innovation backed by robust regulatory compliance. As they continue to expand their footprint across approximately 40 countries with their advanced offerings, stakeholders from various sectors will undoubtedly keep a close watch on future developments.

For specific inquiries or to delve deeper into Bioretec's offerings, interested parties can visit their official website at www.bioretec.com. This commitment to transparency in operations underscores their forward-thinking approach, inviting further interest from investors and healthcare providers alike.